In short
Clinical trials investigating Adapalene are studying acne treatment in people with moderate facial acne, including skin of color patients. These trials look at how Adapalene is used in standard care and compare treatment approaches by measuring outcomes such as skin changes and acne-related results.
Key points
- Clinical trials investigating Adapalene in the provided data focus on acne, especially moderate facial acne in skin of color patients. The listed study is a Phase 3 interventional trial with 420 planned participants. It compares early oral isotretinoin with standard of care that includes treatments such as Adapalene. The main result being measured is ARP severity at 6 months using facial pictures and a scoring system. The study aims to see whether early treatment can improve skin outcomes in this patient group.
Trial overview
The source data includes one interventional clinical trial that investigates treatment for acne and lists Adapalene among the study drugs. The trial is authorised and plans to enroll 420 participants.
The study title shows that researchers are comparing oral isotretinoin with standard of care in people with moderate acne and skin of color. The brief summary says the goal is to test whether early treatment improves the severity of ARP at 6 months.
Who is being studied
The trial focuses on patients with moderate facial acne. It also specifically includes skin of color patients, which means people with darker skin tones.
The source data does not give a full list of entry rules, so only the population named in the trial record can be described here. Based on the title and summary, the study is aimed at people who need treatment for acne on the face.
Treatments in the study
Adapalene appears in the intervention list as ADAPALENE ZENTIVA 0,1 %, crème, which is a cutaneous, or skin, treatment. The record also lists other acne treatments used in the study setting, including oral isotretinoin, doxycycline, lymecycline, and other topical products.
The trial title and summary show that the main comparison is between early oral isotretinoin and the current standard of care. Adapalene is part of the treatment list, but the source data does not say that it is the main treatment being tested alone.
- Topical treatment means a medicine applied to the skin, not taken by mouth.
- Oral treatment means a medicine taken by mouth as a capsule or tablet.
- Standard of care means the usual treatment used in regular medical practice.
Study phase and design
This is a Phase 3 trial. Phase 3 studies usually involve larger groups of patients and compare treatment results in real-world-like settings.
The study type is listed as interventional, which means the research team gives treatments and measures the effects. The enrollment target is 420 participants, showing that this is a fairly large study for acne research.
Main outcome being measured
The primary outcome is the ARP severity score, measured from facial pictures, including selfies, at month 6. The score ranges from 0 to 4, where 0 means no ARP and 4 means severe ARP.
In this study, success is defined as a score below 2 at month 6, which means no or very mild ARP. The record explains that this scoring method was developed for hyperpigmented skin changes and is validated in dark skin types.
- Primary outcome is the main result the researchers want to measure.
- Validated means the method has been checked and shown to work for the group being studied.
- Hyperpigmented lesions are darker spots or patches on the skin.
What the trial means for patients
For patients, this trial shows that Adapalene is being studied in the context of acne care, especially where skin changes after acne are a concern. The study is not mainly about Adapalene alone, but about acne treatment strategies that include it among other standard options.
The most important research question is whether early treatment can improve the skin outcome measured by ARP severity at 6 months. Because the study focuses on moderate facial acne in skin of color patients, it may help answer questions that matter for this specific group.